All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group

Basilea bins IPO, gets Sfr200m via CB/rights

Basilea Pharmaceutica scientist for web

The equity-linked market in Europe has been quiet since Total SA’s $1.2bn deal on November 25, but on Wednesday a very different deal was executed successfully by Basilea Pharmaceutica, a small and still unprofitable Swiss drug company.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree